| | |
| Clinical data | |
|---|---|
| Other names | 3,4-Methylenedioxy-N-propylamphetamine; MDPR; N-Propyl-MDA |
| Routes of administration | Oral [1] |
| Drug class | Psychoactive drug [1] |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | Unknown [1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.217.125 |
| Chemical and physical data | |
| Formula | C13H19NO2 |
| Molar mass | 221.300 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
MDPR, also known as 3,4-methylenedioxy-N-propylamphetamine or as N-propyl-MDA, is a lesser-known psychoactive drug and a substituted amphetamine. [1] [2]
In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists MDPR's minimum dose as 200 mg orally and its duration as unknown. [1] [2] MDPR is described as a "promoter"; by itself it has almost no effects on the mind, but it promotes the effects of hallucinogens, similarly to the closely related MDPH. [1] Shulgin reported that 160 mg of MDPR strongly enhanced the effects of a small (60 μg) dose of LSD, [1] and that similar enhancement of hallucinogenic effect was noted when mixing MDPR with other drugs such as psilocybin, mescaline, 2C-B, and 2C-T-7. [1] The reason for this synergistic action of MDPR has not been elucidated. [1]